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ABSTRACT 
Background:  The STarT Back strategy for categorizing and treating patients with low back pain 
(LBP) improved patients’ function while reducing costs in England.  
 
Objective:  This trial evaluated the effect of implementing an adaptation of this approach in a 
United States (U.S.) setting.  
 
Design: The Matching Appropriate Treatments to Consumers Healthcare needs (MATCH) trial 
was a pragmatic cluster randomized trial with a pre-intervention baseline period.  Six primary care 
clinics were pair-randomized, three to training in the STarT Back strategy and three to serve as 
controls. 
Participants:  Adults receiving primary care for non-specific LBP were invited to provide data 2 
weeks after their primary care visit and follow-up data 2 and 6 months (primary endpoint) later.   
Interventions:  The STarT Back risk-stratification strategy matches treatments for LBP to physical 
and psychosocial obstacles to recovery using patient-reported data (the STarT Back Tool) to 
categorize patients’ -risk of persistent disabling pain.  Primary care clinicians in the intervention 
group attended 6 didactic sessions to improve their understanding LBP  management and 
received in-person training in the use of the tool that had been incorporated into the electronic 
health record (EHR).  Physical therapists received 5 days of intensive training.  Control clinics 
received no training.   
 
Main Measures:  Primary outcomes were back-related physical function and pain severity.  
Intervention effects were estimated by comparing mean changes in patient outcomes after 2 and 
6 months between intervention and control clinics. Differences in change scores by trial arm and 
time period were estimated using linear mixed effect models.  Secondary outcomes included 
healthcare utilization. 
Key Results:  Although clinicians used the tool for about half of their patients, they did not change 
the treatments they recommended.  The intervention had no significant effect on patient 
outcomes or healthcare use.   
Conclusions:  A resource-intensive intervention to support stratified care for LBP in a U.S. 
healthcare setting had no effect on patient outcomes or healthcare use.  
 
307 words 
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Abbreviations 
CAM:  Complementary and alternative medicine 
CBT:  Cognitive behavioral therapy 
DVD:  Digital video disc 
CATI:  Computer-assisted telephone interview 
CME:  Continuing medical education 
EHR:  Electronic health record 
GAD:  Generalized anxiety disorder 
GH:  Group Health 
GLMM:  Generalized linear mixed models 
LMM:  Linear mixed models 
MATCH:  Matching Appropriate Treatments to Consumers Healthcare needs 
NIH:  National Institutes of Health 
PC:  Primary care 
PCORI:  Patient Centered Outcomes Research Institute 
PCP:  Primary care provider 
PGIC:  Patient Global Impression of Change 
PHQ:  Patient Health Questionnaire 
PSEQ:  Pain Self Efficacy Questionnaire 
PT:  Physical therapy/physical therapist 
RMDQ:  Roland-Morris Disability Questionnaire 
RS:  Risk stratification 
STarT:  Subgroups for Targeted Treatment” Risk Stratification  
TSK:  Tampa Scale of Kinesiophobia 
UC:  Usual Care 
US:  United States 
WPAI:  Work Productivity and Activity Impairment 
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INTRODUCTION 
Despite increasing U.S. expenditures for low back pain (LBP), patient outcomes have 
deteriorated (1).  The current epidemic of opioid addiction and deaths illustrates the urgency of 
finding safer and more effective approaches for chronic pain (2, 3). The traditional view of LBP as 
a largely biomedical problem (4) is being supplanted by the biopsychosocial model that 
acknowledges that while pain usually has an underlying biological basis, psychosocial factors 
(e.g., pain beliefs/cognitions, distress, coping behaviors and social factors) also significantly 
influence the experience and impact of pain (5, 6).  This broader conceptualization provides a 
clear rationale for incorporating cognitive behavioral principles into the management of distressed 
and disabled patients with chronic LBP to minimize pain-related disability. 
A promising strategy for categorizing and treating patients considering both their 
physical and psychosocial characteristics, the STarT Back approach, was developed and 
evaluated in England (7).  This approach improved patients’ physical function and 
satisfaction with care while reducing costs (8-11).  This strategy uses patient responses to 
a 9-item “STarT Back tool” questionnaire to allocate patients to a low, medium or high-risk 
subgroup according to their risk of persistent disabling back pain.  Patients in each 
subgroup are then recommended evidence-based treatments matched to their prognostic 
profile (7, 12, 13).  Patients found to have at least 4 out of the 5 “psychosocial” risk factors 
(high pain bothersomeness, fear, worry, catastrophizing, depression) are “high risk” and 
those with relatively few (0-3) physical or psychosocial risk factors are “low risk”. The 
remaining patients with significant pain and/or activity limitations but fewer psychosocial 
risk factors are “medium risk”. This tool has been validated with primary care adults with 
non-specific LBP (12). The success of this strategy in England. has generated great 
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interest in developed countries, providing new hope that meaningful improvements in 
primary care for LBP are within reach (14-19).   
Prior to widespread implementation, it would be valuable to know if the STarT Back strategy 
can be successfully translated to other settings.   To determine if the STarT Back risk 
stratification strategy would succeed in the U.S., we conducted the MATCH (Matching 
Appropriate Treatments to Consumers Healthcare needs) cluster randomized trial.  This trial 
evaluates the effects of incorporating the STarT Back strategy into primary care practices within 
an integrated healthcare system. The goal was to give primary care providers (PCPs) and 
physical therapists the knowledge, tools, and confidence they needed to provide their patients 
with a broader understanding of their LBP, reassurance about their likely prognosis, and 
treatment options that matched the patients’ prognostic profile.  We hypothesized this intervention 
would improve patient outcomes by promoting increased use of matched treatment options for 
patients in each subgroup, as determined by the STarT Back tool. We believe this is the first 
randomized and controlled evaluation of the STarT Back approach to improve care for back pain 
in the U.S. 
 
METHODS 
Design and Setting 
The trial design has been reported in detail (20).  In brief, MATCH was a pragmatic, cluster 
randomized trial with two parallel arms (21) each with a baseline data collection period.  Six 
primary care clinics were randomized in 1:1 ratio to intervention or control (Figure 1).  PCPs were 
either MDs (84%) or Physician Assistant/Nurse practitioners (16%); 85% had practiced over 5 
years; and 62% were female.  Data were collected from patients and electronic health records 
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(EHR). The trial was conducted in Group Health (GH), an integrated healthcare delivery system 
in Washington State serving over 600,000 members. 
GH partnered with the research team to evaluate the effect of stratified care in its primary care 
clinics.  The intervention was incorporated into a mandatory care improvement activity, fully 
supported by clinical and administrative leadership.  
 
Participating Clinics (Clusters) and Patients 
One clinic from each of 3 pairs of 6 large primary care clinics (with onsite physical therapy) 
near Seattle was matched on geographic and socioeconomic characteristics and pair-randomized 
to the intervention or control.  Control clinics received no intervention.  Pre-intervention levels of 
patient outcomes were measured in all 6 clinics.  The intervention was then implemented in 
intervention clinics over 6 months, after which patient outcomes were again assessed in both 
intervention and control clinics.   
 During the trial, all patients 18+ years of age identified in the EHR as having received a 
primary diagnosis consistent with non-specific LBP (e.g., lumbago, back pain not otherwise 
specified) were eligible to participate  To maintain broad applicability, we only excluded patients 
with specific causes of pain (e.g., pregnancy, disc herniation, vertebral fracture, spinal stenosis) 
or with job injuries, which were seen in the Occupational Medicine clinic.  
 
Randomization and Blinding 
Prior to the intervention, the trial biostatistician randomly assigned one clinic in each of the 3 
geographic and sociodemographic matched pairs of clinics to the intervention by computer-
generated random number.  All eligible patients seen in the intervention clinics were considered 
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to have received the intervention.  Researchers did not inform patients that their clinics were 
participating in an intervention.  Interviewers were blinded to patients’ clinics. 
 
The Intervention 
The intervention was implemented in the 3 intervention clinics from April-September 2014. Key 
components of the intervention were incorporating the original version of the STarT Back tool (8) 
into the EHR, identifying recommended treatment options available from GH for patients in each 
risk subgroup, and training the primary care teams and physical therapists (Appendix 1 online) 
(20).   
 
Outcomes 
Patient outcome data were collected by telephone interviewers during the pre-intervention 
(November 2013 – April 2014) and post-intervention (December 2014 – August 2016) periods.  
Interviews occurred 2 weeks (range: 1 to 3 weeks) after the LBP visit (baseline) and again two 
and six months later. Primary outcomes were:  LBP-related physical function in the previous 
week (measured with the modified Roland-Morris Disability Questionnaire (RMDQ) (22)) and LBP 
severity during the previous week (measured on a 0-to-10 scale where 0 represents "no pain" 
and 10 "pain as bad as it could be") (23).  Secondary outcomes included patient outcomes 
(depression, anxiety, fear of movement, global improvement, self-efficacy, satisfaction, and work 
productivity and activity impairment (20)) and actual healthcare utilization from the automated 
EHR (e.g., lumbar imaging, physical therapy, complementary and alternative medical therapies, 
cognitive behavioral therapy, opioids, spinal injections and spine surgeon consultations).  
Because the intervention targeted PCPs, we could not identify adverse effects. 
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Data Collection  
The pre-intervention period was devoted to measuring changes in patient outcomes 2 and 6 
months after LBP visits in the intervention and control clinics.  Because collecting baseline data 
during the visit was not feasible, we mailed patients letters shortly after the visits explaining GH 
was conducting a study to improve LBP care and that we would call to invite their participation. 
Patients not wishing to be contacted were provided a phone number to opt out. Research 
specialists called patients between 1 and 3 weeks after their visit to explain the study, answer 
questions, confirm eligibility and obtain verbal informed consent to complete a baseline and two 
follow-up interviews. Patients were paid $20 for each questionnaire. Trained interviewers used 
computer-assisted telephone interviewing to minimize errors and missing data.  Similar methods 
were used to collect post-intervention data.  Because we did not meet our recruitment goal during 
the pre-intervention period, we increased post-intervention recruitment to maintain overall 
statistical power (see Sample Size section).  We also improved the recruitment letter, increased 
staffing, and lengthened the recruitment period.  The mean interval between visit date and 
baseline data collection was 12.7 (SD=7.1) days.  
 
Sample Size 
A priori sample size calculations were performed targeting 80% power to detect a 1.5 point 
difference in 6-month LBP-related change in patient function (RMDQ) pre- and post-intervention 
between control and intervention clinics (0 point difference in the low risk subgroups and 2.5 
points difference in medium and high risk subgroups) and 0.9 points on LBP pain severity score 
(0 point difference in low risk subgroups and 1.5 points difference in medium and high risk 
subgroups). We planned for a sample size of 1,760 participants balanced equally between the 
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pre- and post-intervention periods and the control and intervention clinics allowing for a loss to 
follow-up rate of 20% (20). Because we recruited only 603 participants (goal was 880) during the 
pre-intervention period we determined that we would need a sample size of 1,334 during the 
post-intervention period to maintain 80% power. The final numbers recruited were 603 
participants in the pre-intervention period (546 with complete follow-up) and 1098 in the post-
intervention period (1008 with complete follow-up). Our post-hoc calculation of power based on 
the observed data (accounting for imbalance between intervention arms) found we had 80% 
power to detect a difference between trial arms of 1.5 points on the change in RMDQ score 
before and after the intervention. We assumed no correlation of outcomes within provider or 
clinic.   
 
Statistical Methods 
We first estimated the change in mean score by clinic assignment between the pre- and post-
intervention periods.  We then compared these differences to estimate the change attributable to 
the intervention (i.e., we made inferences on the interaction between clinic assignment and 
intervention period). We used a linear mixed effects model with random effects (24) for patient 
participants (repeated outcome measurements on participants at 2 and 6 months post LBP visit) 
and clinic (randomization at clinic level) to account for correlation within individuals and clinics. 
The primary analysis time-point was 6 months following the LBP visit. To account for potential 
confounding variables, we adjusted for participant-level baseline covariates shown to be 
associated with LBP physical function and pain intensity, as well as variables that were 
imbalanced at baseline at the patient level between intervention and control arms: sex, age, 
education, race, employment, function (RMDQ) and pain intensity.  Risk-subgroup specific 
estimates and secondary outcomes were calculated using an identical framework to that 
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described above with one exception. For binary secondary outcomes we used generalized linear 
mixed models (GLMM) (25) with logit and/or log link functions to estimate odds ratios and/or 
relative risks instead of mean change scores. We assumed the standard alpha level of 0.05 for a 
two-sided test. 
We used the same analytic approach with EHR data to evaluate the effect of the intervention 
on healthcare utilization for LBP. We examined if the use of -recommended treatments for 
patients at medium and high-risk of persistent disabling pain increased and the use of treatments 
generally not recommended for non-specific LBP decreased.  The primary analyses included all 
eligible patients (not just those providing patient data). We also analyzed data for the subset of 
patients who participated in the telephone questionnaires.  Comparison of the data from these 
two populations allowed us to determine the representativeness of participants. We also 
examined the frequency with which STarT Back risk scores were recorded in the EHR.  See 
reference 20 for more detail.   
 
RESULTS 
Patient Recruitment and Follow-up 
Figure 1 presents the flow diagram showing the 6 clinics in this cluster RCT and the flow of 
trial participants.  Because we included a pre-intervention “baseline” period, we present flow data 
for both the pre- and post-intervention periods as well as for the total.  A total of 2,138 LBP 
patients visited the intervention clinics and 2,571 the control clinics.  Characteristics of 
intervention and control patients were similar both pre- and post-intervention.  Overall, 36% of 
patients provided baseline data on the telephone.  Participating patients were slightly older than 
non-participants (mean ages of 57.1 and 54.8, respectively) and more likely to be white (83.0% 
and 77.0%, respectively but did not differ by gender.  Follow-up rates were 93% at 2 months and 
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91% at 6 months.  Participation and follow-up rates were similar in the intervention and control 
clinics. 
 
Patient Characteristics (Table 1) 
Reflecting the GH membership, participants had relatively high levels of education and income 
and were primarily white and non-Hispanic.  About half the participants were over 60 years old.  
Participants had moderately high levels of functional disability and pain severity, 56% had 
episodes lasting less than 3 months, 48% reported leg pain, and about 30% were using opioids 
for their pain. Data from the STarT Back tool showed that 41% were categorized at low-risk, 37% 
at medium-risk, and 22% at high-risk of persistent disabling pain.  The STarT Back tool 
successfully predicted the prognoses of the three risk groups (i.e., the high-risk group had the 
worst outcomes and the low-risk group had the best outcomes) [Submitted].  Participants’ 
characteristics were similar in the intervention and control arms, showing no evidence of selection 
bias. 
Effect of the Intervention 
Patient outcomes:  At 6 months, there were no statistically significant differences between 
participants in the intervention and control arms for either primary patient outcome overall or 
within risk subgroup (Table 2) or for secondary patient outcomes (Table 3).  The absolute 
magnitudes of the between group differences were small and for the primary outcome measures 
slightly favored the control group.   Similar results were found at 2-months (Appendix 2 online). 
Healthcare utilization:  STarT Back tool data were available for about 50% of LBP visits during 
the 6-month intervention period, decreasing to about 40% over the ensuing 20 months.  Among 
the 32 PCPs in the intervention clinics who saw at least 10 patients with LBP during both the 
intervention period and post-intervention period, the median percentage of visits with a STarT 
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Back tool score in the EHR was 47% (range 23%-71%) during the intervention period and 42% 
(range 8%-71%) during the post-intervention period.  Thus, the tool continued to be used for 
patients of all PCPs, at least occasionally, long after the intervention ended.  
Despite PCP or nursing staff entry of the STarT Back tool data for almost half of the visits for 
LBP, knowledge of the patients’ risk subgroup did not affect the type or frequency of healthcare 
provided (Table 4).  Specifically, there was no evidence that the intervention strategies used in 
the MATCH trial increased the use of treatments recommended for medium and high risk patients 
(e.g., physical therapy, complementary and alternative medicine, or cognitive behavioral therapy), 
or decreased the use of non-recommended tests or treatments (i.e., imaging, opioid medications, 
spine injections, surgical referrals) for LBP patients at any risk level.  There was no evidence of 
any changes in the tests or treatments recommended by clinicians in the intervention clinics for 
any of the patient risk subgroups (Table 5).  A pre-specified secondary analysis restricted to 
patients providing telephone outcome data showed similar results.   
 
DISCUSSION 
The MATCH trial is the first major evaluation of implementation of an adaption of the STarT 
Back risk stratification strategy in the U.S. Although the intervention resulted in use of the STarT 
Back tool for approximately half of patient visits for LBP, it did not change PCP treatment 
decisions.  Another recent cluster randomized controlled trial evaluated use of a multifaceted 
strategy (including embedding the STarT Back Tool in the EHR) to implement LBP guidelines into 
Danish general practices (26).  That trial found lower secondary care referral rates in the 
intervention clinics (5.0%) than in the control clinics (10.5%) but no improvement in patient 
outcomes.    
14 
  
There are many reasons complex interventions such as the one evaluated in this trial could 
fail to improve patient outcomes, including unacceptability to clinicians, inadequate leadership 
and system support, ineffective implementation, and inadequate potency.  Although a 
comprehensive evaluation of the implementation process found high levels of clinician 
engagement and system support (submitted), there were limitations in our intervention that could 
explain why PCP behavior did not change, most notably:  1) we did not conduct feedback audits 
to encourage clinician adherence to matching treatments to patient subgroups, 2) compared with 
English studies (8,9), our matched treatment options were more numerous, less familiar to 
clinicians, and more difficult to access, thereby placing a greater burden on our PCPs.  We also 
used a different recruitment strategy than the English studies.  Differences between England (9) 
and our study population could also explain outcome differences.  For example, although the 
patient populations were similar in age, gender, employment, risk subgroup proportions, and pain 
severity, U.S. patients had substantially higher baseline levels of LBP-related physical disability 
(RMDQ scores of 11.8 vs. 8.4, respectively).  
We designed our intervention (20) to be as potent as possible without making it impossible to 
implement in primary care clinics. Even if our intervention had improved outcomes, it may not 
have been feasible to implement in most U.S. primary care settings.  The high levels of burnout 
among PCPs and the continued turmoil in U.S. healthcare (27), make complex changes in clinical 
practice difficult. 
Major strengths of the MATCH trial include randomization of matched pairs of clinics to serve 
as intervention or control clinics, adequate sample sizes and power to detect meaningful 
differences, high follow-up rates, and an adaptive and pragmatic intervention design including 
substantial PCP and physical therapist training, training modules based on requests of primary 
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care teams, and inclusion of the whole primary care team (20).  Limitations include less than half 
of all LBP patients participated and may not be representative of all patients, the need to defer 
baseline data collection until 2 weeks after the PCP visit thereby missing any early treatment 
effects, and the restriction to a single socio-economically homogenous integrated healthcare 
system. 
 
CONCLUSIONS 
In contrast to the positive results of implementing a risk stratification strategy to improve 
primary care for LBP in England (15, 16), our adaptation of that strategy to the different 
circumstances in our setting did not change healthcare utilization or improve patient outcomes.  
This illustrates the risk of failure when complex interventions developed and found effective in 
one setting are implemented in a different setting even with strong system support and 
substantial resources devoted to adapting the intervention to local needs and circumstances. 
To increase their the chances of success, future initiatives to implement complex interventions 
in primary care should include simple and easily implemented and supported treatment 
recommendations, automatic alerts in the EHR to make it easy for clinicians to remember to 
collect risk-stratification information and recommend appropriate matched treatments to their 
patients, and the provision of regular feedback on their performance adhering to the matched 
treatment recommendations for patients at each risk stratum are likely to improve the chances of 
success.  Given the limited ability of primary care clinicians to take on new responsibilities, 
however, innovative approaches (e.g., expanded nurse role) may be necessary to promote the 
clinical changes necessary to improve patient outcomes. 
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Figure 1:  Flow of Patients Through Trial 
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Table 1.Baseline characteristics of study participants  in the control (n=3) and intervention (n=3) clinics  
 Control Intervention 
Characteristic (n=945) (N=756) 
Sex, female, No. (%) 512 (54.2) 441 (58.3) 
Age, mean (SD), y 55 (17.3) 58 (18.4) 
18-39, No. (%) 215 (22.7) 160 (21.1) 
40-59, No. (%) 310 (32.8) 204 (26.9) 
60+, No. (%) 420 (44.4) 392 (51.8) 
Education     
High school or less, No. (%) 143 (15.1) 105 (13.9) 
Some College, No. (%) 303 (32.1) 231 (30.6) 
College/Post-graduate, No. (%) 498 (52.8) 418 (55.4) 
Income*     
<$35K, No. (%) 161 (18.3) 141 (20.2) 
$45-55K, No. (%) 203 (23.1) 186 (26.6) 
$55-85K No. (%) 216 (24.6) 149 (21.3) 
$85K+, No. (%) 298 (33.9) 223 (31.9) 
Employed, No. (%) 557 (58.9) 417 (55.2) 
White, No. (%)* 743 (79.9) 582 (78.0) 
Hispanic, No. (%)* 53 (5.8) 40 (5.5) 
Back-related function (RMDQ),(0-23 scale) mean (SD)# 11.8 (6.3) 11.8 (6.1) 
Back pain Severity, (0 - 10 scale), mean (SD)## 5.4 (2.5) 5.5 (2.5) 
STarT Back Risk Group     
Low, No. (%) 392 (41.5) 305 (40.3) 
Medium, No. (%) 348 (36.8) 286 (37.8) 
High, No. (%) 205 (21.7) 165 (21.8) 
Duration of  current episode of LBP@ 
 
    
      <3 months (%) 186 (56,4) 153 (56.0) 
      3-12 months (%)   58 (17.6)   47 (17.2) 
       12 months (%)   86 (26.0)   73 (26.7) 
Hrs. of work missed past week due to LBP, mean (SD) 4.4 (10.4) 3.6 (8.9) 
Effect of LBP on work in past week (0-10), mean (SD) 3.0 (2.9) 3.0 (2.7) 
Leg pain in leg, No. (%) 457 (48.4) 360 (47.7) 
Anxiety (GAD-7), mean (SD) 4.2 (4.6) 4.4 (4.6) 
Depression (PHQ-8), mean (SD) 6.1 (5.4) 6.2 (5.3) 
Self-efficacy (PSEQ), mean (SD) 44.4 (13.3) 45.0 (12.7) 
Fear of movement (TKS),  mean (SD) 39.7 (10.1) 39.4 (10.3) 
Used medications for back pain in past week, No. (%) 735 (77.8) 570 (75.5) 
Used narcotics for back pain in past week, No.  (%) 104 (31.5) 76 (27.8) 
 
* Missing data:  Income and pain duration (7%), race and Hispanic (3%), hours of work missed (1%). 
All other variables had <1% missing.     
# Higher scores indicate greater dysfunction     
## Higher scores indicate greater pain severity 
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Abbreviations:  LBP=low back pain; GAD=generalized anxiety disorder; PHQ=patient health questionnaire 
PSEC=patient self-efficacy questionnaire; TSK=Tampa Scale for Kinesiophobia; RMDQ=Roland-Morris 
Disability Questionnaire     
@  Pain duration was measured only during the pre-implementation period, resulting in smaller sample sizes than for the other 
measures. 
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Table 2.  Primary outcomes main analysis and by risk subgroup at 6 month follow-up 
 Pre-Intervention Period Post-Intervention Period    
 N Change 95% CI N Change 95% CI Difference 95% CI 
Function (RMDQ)            
Main Analysis            
Control Clinics 297 -3.33 (-4.18, -2.49) 546 -3.89 (-4.64, -3.14) -0.55 (-1.26, 0.15) 
Intervention Clinics 245 -3.98 (-4.86, -3.09) 428 -4.03 (-4.81, -3.25) -0.05 (-0.83, 0.73) 
Difference  -0.64 (-1.86, 0.58)  -0.14 (-1.22, 0.94) 0.50 (-0.55, 1.55) 
P-Value           0.349 
 
Subgroup, Low Risk 
           
Control Clinics 122 -5.18 (-5.98, -4.39) 234 -5.75 (-6.37, -5.12) -0.56 (-1.42, 0.29) 
Intervention Clinics 109 -5.60 (-6.41, -4.78) 170 -5.60 (-6.29, -4.91) -0.01 (-0.94, 0.93) 
Difference  -0.41 (-1.48, 0.65)  0.14 (-0.70, 0.98) 0.56 (-0.71, 1.82) 
P-Value           0.389 
 
Subgroup, Moderate Risk 
Control Clinics 108 -3.54 (-5.11, -1.97) 203 -3.90 (-5.30, -2.50) -0.36 (-1.61, 0.89) 
Intervention Clinics 88 -3.34 (-4.98, -1.70) 165 -3.77 (-5.21, -2.32) -0.43 (-1.82, 0.96) 
Difference  0.20 (-2.06, 2.46)  0.13 (-1.86, 2.13) -0.06 (-1.94, 1.81) 
P-Value           0.946 
 
Subgroup, High Risk 
           
Control Clinics 67 -1.42 (-3.33, 0.49) 109 -2.49 (-4.15, -0.82) -1.07 (-2.92, 0.79) 
Intervention Clinics 48 -3.78 (-5.82, -1.74) 93 -3.09 (-4.77, -1.41) 0.69 (-1.46, 2.84) 
Difference  -2.36 (-4.77, 0.05)  -0.60 (-2.48, 1.27) 1.76 (-1.10, 4.62) 
P-Value           0.229 
 
Pain Intensity 
           
Main Analysis            
Control Clinics 297 -1.64 (-1.94, -1.34) 534 -1.96 (-2.20, -1.72) -0.32 (-0.66, 0.01) 
Intervention Clinics 245 -1.81 (-2.13, -1.48) 415 -2.00 (-2.26, -1.74) -0.19 (-0.56, 0.18) 
Difference  -0.17 (-0.61, 0.27)  -0.039 (-0.39, 0.31) 0.13 (-0.37, 0.63) 
P-Value           0.61 
Subgroup, Low Risk            
Control Clinics 122 -2.13 (-2.54, -1.72) 228 -2.25 (-2.56, -1.94) -0.12 (-0.59, 0.35) 
Intervention Clinics 109 -2.27 (-2.69, -1.85) 168 -2.42 (-2.78, -2.07) -0.15 (-0.66, 0.36) 
Difference  -0.14 (-0.69, 0.41)  -0.173 (-0.59, 0.25) -0.03 (-0.72, 0.66) 
P-Value           0.926 
Subgroup, Moderate Risk 
Control Clinics 108 -1.59 (-2.23, -0.95) 200 -1.93 (-2.48, -1.38) -0.34 (-0.91, 0.23) 
Intervention Clinics 88 -1.47 (-2.14, -0.79) 157 -1.79 (-2.37, -1.21) -0.33 (-0.97, 0.32) 
Difference  0.13 (-0.80, 1.05)  0.14 (-0.65, 0.93) 0.02 (-0.85, 0.88) 
P-Value           0.973 
Subgroup, High Risk            
Control Clinics 67 -0.74 (-1.55, 0.07) 106 -1.54 (-2.24, -0.84) -0.8 (-1.62, 0.03) 
Intervention Clinics 48 -1.6 (-2.47, -0.73) 90 -1.54 (-2.25, -0.82) 0.06 (-0.89, 1.01) 
Difference  -0.86 (-1.88, 0.17)  0.002 (-0.79, 0.79) 0.86 (-0.41, 2.12) 
P-Value           0.183 
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Table 3. Secondary patient outcomes at 6-Month Follow-Up  
  Pre-Intervention   Post-Intervention    
 N Change 95% CI N Change 95% CI Difference 95% CI 
CONTINUOUS OUTCOMES 
Depression (PHQ-8)            
Control Clinics 296 -1.90 (-2.39, -1.41) 544 -1.41 (-1.80, -1.03) 0.49 (-0.06, 1.04) 
Intervention Clinics 245 -1.94 (-2.47, -1.41) 427 -1.57 (-1.99, -1.15) 0.36 (-0.24, 0.97) 
Difference  -0.04 (-0.76, 0.68)  -0.16 (-0.73, 0.41) -0.12 (-0.94, 0.70) 
P-Value           0.770 
Anxiety (GAD-7) 
           
Control Clinics 297 1.13 (0.74, 1.51) 541 0.92 (0.64, 1.21) -0.21 (-0.68, 0.27) 
Intervention Clinics 245 1.02 (0.60, 1.45) 425 0.83 (0.50, 1.15) -0.20 (-0.73, 0.33) 
Difference  -0.10 (-0.67, 0.47)  -0.10 (-0.53, 0.33) 0.01 (-0.71, 0.72) 
P-Value           0.988 
Fear of Movement (TSK) 
Control Clinics 297 -4.19 (-5.19, -3.18) 537 -4.31 (-5.10, -3.52) -0.12 (-1.27, 1.02) 
Intervention Clinics 244 -4.53 (-5.63, -3.44) 422 -4.08 (-4.95, -3.21) 0.46 (-0.82, 1.73) 
Difference  -0.35 (-1.83, 1.14)  0.23 (-0.95, 1.41) 0.58 (-1.13, 2.29) 
P-Value           0.506 
Self-Efficacy (PSEQ) 
           
Control Clinics 297 3.17 (1.94, 4.40) 543 3.96 (2.97, 4.94) 0.79 (-0.56, 2.13) 
Intervention Clinics 244 3.25 (1.92, 4.58) 423 4.31 (3.23, 5.39) 1.06 (-0.44, 2.56) 
Difference  0.08 (-1.73, 1.89)  0.36 (-1.11, 1.81) 0.28 (-1.74, 2.29) 
P-Value           0.789 
Effect on Work Productivity 
Control Clinics 155 -1.37 (-1.69, -1.05) 284 -1.44 (-1.69, -1.20) -0.08 (-0.45, 0.30) 
Intervention Clinics 119 -1.68 (-2.04, -1.32) 209 -1.45 (-1.73, -1.17) 0.23 (-0.20, 0.67) 
Difference  -0.32 (-0.80, 0.16)  -0.01 (-0.38, 0.36) 0.31 (-0.26, 0.88) 
P-Value           0.288 
Hours of Work Lost Due to BP 
Control Clinics 155 -2.41 (-3.20, -1.61) 283 -2.94 (-3.53, -2.35) -0.53 (-1.52, 0.46) 
Intervention Clinics 119 -3.33 (-4.24, -2.42) 209 -2.49 (-3.17, -1.81) 0.84 (-0.30, 1.98) 
Difference  -0.92 (-2.13, 0.28)  0.45 (-0.45, 1.35) 1.37 (-0.13, 2.88) 
P-Value           0.074 
BINARY OUTCOMES 
 
   
 
      
 N Prop. 95% CI N Prop. 95% CI OR 95% CI 
Very satisfied with care 
Control Clinics 284 0.50 (0.33, 0.67) 519 0.56 (0.42, 0.70) 1.27 (0.83, 1.94) 
Intervention Clinics 235 0.41 (0.25, 0.56) 420 0.41 (0.29, 0.52) 1.01 (0.63, 1.61) 
24 
  
OR  0.69 (0.42, 1.15)  0.55 (0.37, 0.80) 0.79 (0.42, 1.49) 
P-Value           0.471 
 
  
Very satisfied with treatment 
Control Clinics 256 0.41 (0.26, 0.55) 415 0.38 (0.27, 0.49) 0.91 (0.57, 1.44) 
Intervention Clinics 209 0.26 (0.15, 0.37) 333 0.29 (0.19, 0.38) 1.15 (0.68, 1.95) 
OR  0.51 (0.29, 0.89)  0.65 (0.42, 1.00) 1.26 (0.63, 2.54) 
P-Value           0.516 
Very satisfied with information about cause of pain 
Control Clinics 289 0.31 (0.19, 0.43) 517 0.41 (0.29, 0.52) 1.52 (0.94, 2.46) 
Intervention Clinics 243 0.30 (0.17, 0.43) 416 0.36 (0.24, 0.48) 1.29 (0.76, 2.20) 
OR  0.967 0.54 1.72  0.82 0.53 1.26 0.85 0.41 1.740 
P-Value           0.65 
Completely recovered or much better (PGIC) 
Control Clinics 297 0.26 (0.15, 0.36) 537 0.34 (0.24, 0.44) 1.51 (0.93, 2.46) 
Intervention Clinics 245 0.31 (0.17, 0.44) 423 0.38 (0.26, 0.51) 1.38 (0.81, 2.37) 
OR  1.31 (0.73, 2.33)  1.19 (0.77, 1.84) 0.91 (0.44, 1.89) 
P-Value           0.810 
25 
  
Table 4. Pre-post proportion and odds ratio (OR)  for selected health services for low back pain 
between the control and intervention arms in the six months after visit 
 Pre-Intervention Period Post-Intervention Period    
 N Prop 95% CI N Prop 95% CI OR 95% CI 
Lumbar spine imaging*            
Control Clinics 1061 0.14 (0.07, 0.22) 1473 0.18 (0.09, 0.27) 1.34 (1.08, 1.67) 
Intervention Clinics 943 0.16 (0.08, 0.25) 1163 0.22 (0.11, 0.34) 1.46 (1.17, 1.84) 
OR  1.20 (0.57, 2.54)  1.31 (0.63, 2.73) 1.09 (0.80, 1.50) 
P-value           0.578 
Additional primary care visits 
Control 1061 0.15 (0.12, 0.17) 1473 0.24 (0.21, 0.27) 1.86 (1.51, 2.29) 
Intervention 943 0.12 (0.09, 0.14) 1163 0.24 (0.21, 0.28) 2.43 (1.91, 3.10) 
OR  0.77 (0.59, 1.01)  1.01 (0.82, 1.23) 1.31 (0.95, 1.79) 
P-value           0.095 
Emergency  department visits 
Control Clinics 1061 0.05 (0.04, 0.06) 1473 0.04 (0.03, 0.05) 0.77 (0.53, 1.11) 
Intervention Clinics 943 0.04 (0.03, 0.06) 1163 0.03 (0.02, 0.04) 0.75 (0.48, 1.18) 
OR  0.81 (0.54, 1.23)  0.80 (0.53, 1.21) 0.98 (0.55, 1.76) 
P-value           0.959 
Narcotic analgesics 
           
Control Clinics 1061 0.39 (0.30, 0.48) 1473 0.45 (0.35, 0.55) 1.28 (1.07, 1.53) 
Intervention Clinics 943 0.37 (0.28, 0.45) 1163 0.41 (0.32, 0.51) 1.23 (1.01, 1.49) 
OR  0.91 (0.65, 1.27)  0.87 (0.64, 1.20) 0.96 (0.74, 1.25) 
P-value           0.757 
Physical therapy visits 
           
Control Clinics 1061 0.21 (0.15, 0.28) 1473 0.22 (0.15, 0.29) 1.04 (0.86, 1.26) 
Intervention Clinics 943 0.24 (0.16, 0.31) 1163 0.26 (0.18, 0.34) 1.13 (0.93, 1.38) 
OR  1.13 (0.73, 1.76)  1.23 (0.81, 1.89) 1.09 (0.83, 1.43) 
P-value           0.546 
CAM Visits 
           
Control Clinics 1061 0.14 (0.12, 0.17) 1473 0.14 (0.12, 0.16) 0.94 (0.75, 1.18) 
Intervention Clinics 943 0.11 (0.09, 0.13) 1163 0.12 (0.10, 0.15) 1.12 (0.85, 1.46) 
OR  0.74 (0.57, 0.97)  0.88 (0.70, 1.12) 1.19 (0.83, 1.70) 
P-value           0.338 
Behavioral health visits 
           
Control Clinics 1061 0.00 (0.00, 0.01) 1473 0.00 (0.00, 0.00) 0.76 (0.18, 3.15) 
Intervention Clinics 943 0.00 (0.00, 0.01) 1163 0.00 (0.00, 0.00) 0.45 (0.07, 2.77) 
OR  1.13 (0.21, 6.08)  0.67 (0.10, 4.25) 0.59 (0.06, 5.96) 
P-value           0.655 
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Spine surgeon visits            
Control Clinics 1061 0.02 (0.01, 0.03) 1473 0.03 (0.02, 0.03) 1.14 (0.69, 1.90) 
Intervention Clinics 943 0.02 (0.01, 0.03) 1163 0.03 (0.02, 0.04) 1.27 (0.75, 2.17) 
OR  1.02 (0.58, 1.81)  1.14 (0.72, 1.80) 1.11 (0.53, 2.32) 
P-value           0.777 
Injections of lumbar spine 
           
Control Clinics 1061 0.01 (0.00, 0.02) 1473 0.01 (0.00, 0.01) 0.68 (0.32, 1.47) 
Intervention Clinics 943 0.01 (0.00, 0.01) 1163 0.01 (0.00, 0.01) 0.75 (0.28, 2.00) 
OR  0.67 (0.26, 1.68)  0.73 (0.28, 1.92) 1.10 (0.32, 3.82) 
P-value           0.878 
Back-related Hospitalizations 
Control Clinics 1061 0.01 (0.00, 0.02) 1473 0.02 (0.01, 0.02) 1.60 (0.78, 3.29) 
Intervention Clinics 943 0.02 (0.01, 0.03) 1163 0.01 (0.01, 0.02) 0.71 (0.35, 1.43) 
OR  1.80 (0.83, 3.89)  0.80 (0.41, 1.54) 0.44 (0.16, 1.21) 
P-value           0.112 
*Lumbar imaging includes plain films, CT and MRI 
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Table 5. Pre- versus post-intervention odds ratios for selected health services for LBP between the 
control and intervention groups in the six months after an index visit overall and by risk subgroup. Entire 
Study Cohort (n=1699): 
 
 All Study Enrollees         
 Pre-Intervention Period Post-Intervention Period    
 N Prop 95% CI  N Prop 95% CI  OR 95% CI  
Any PT Visits                                                    
Low Risk            
Control 134 0.28 (0.15, 0.40) 258 0.26 (0.16, 0.36) 0.93 (0.58, 1.48) 
Intervention 118 0.27 (0.14, 0.40) 187 0.31 (0.19, 0.44) 1.25 (0.75, 2.08) 
OR                                  0.97 (0.50, 1.86)                                  1.30 (0.76, 2.22) 1.34 (0.67, 2.68) 
P-value                                                                                                                                                                                        0.4 
            
Medium Risk            
Control 120 0.25 (0.09, 0.41) 227 0.32 (0.15, 0.50) 1.45 (0.88, 2.39) 
Intervention 99 0.32 (0.11, 0.53) 187 0.34 (0.15, 0.53) 1.08 (0.64, 1.83) 
OR         1.42 (0.58, 3.49)         1.06 (0.48, 2.31) 0.74 (0.36, 1.53) 
P-value                                                                                 0.42 
            
High Risk            
Control 76 0.27 (0.13, 0.41) 129 0.26 (0.16, 0.36) 0.95 (0.50, 1.82) 
Intervention 56 0.32 (0.14, 0.49) 108 0.36 (0.22, 0.50) 1.20 (0.61, 2.40) 
OR         1.24 (0.58, 2.67)         1.57 (0.90, 2.73) 1.26 (0.49, 3.25) 
P-value                                                                                 0.63 
            
Any CAM Visits                                                    
Low Risk            
Control 134 0.17 (0.08, 0.26) 258 0.13 (0.08, 0.18) 0.71 (0.39, 1.31) 
Intervention 118 0.11 (0.04, 0.17) 187 0.14 (0.08, 0.20) 1.38 (0.67, 2.84) 
OR                                  0.57 (0.27, 1.23)                                  1.11 (0.62, 2.01) 1.94 (0.75, 5.01) 
P-value                                                                                                                                                                                                                     0.17
            
Medium Risk            
Control 120 0.19 (0.10, 0.28) 227 0.17 (0.11, 0.23) 0.85 (0.47, 1.55) 
Intervention 99 0.13 (0.05, 0.21) 187 0.11 (0.06, 0.16) 0.82 (0.39, 1.76) 
OR         0.64 (0.30, 1.37)         0.61 (0.34, 1.09) 0.96 (0.37, 2.52) 
P-value                                                                                 0.94 
            
High Risk            
Control 76 0.27 (0.13, 0.41) 129 0.26 (0.16, 0.36) 0.95 (0.50, 1.82) 
Intervention 56 0.32 (0.14, 0.49) 108 0.36 (0.22, 0.50) 1.20 (0.61, 2.40) 
OR         1.24 (0.58, 2.67)         1.57 (0.90, 2.73) 1.26 (0.49, 3.25) 
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P-value                                                                                 0.63 
Any LBP Imaging            
Low Risk            
Control 134 0.16 (0.00, 0.32) 258 0.20 (0.02, 0.39) 1.30 (0.70, 2.44) 
Intervention 118 0.25 (0.01, 0.49) 187 0.18 (0.01, 0.35) 0.65 (0.37, 1.15) 
OR                                  1.74 (0.44, 6.91)                                  0.86 (0.23, 3.20) 0.50 (0.21, 1.16) 
P-value                                                                                                                                                                                                                     0.11
            
Medium Risk            
Control 120 0.25 (0.07, 0.44) 227 0.16 (0.05, 0.28) 0.57 (0.33, 1.00) 
Intervention 99 0.25 (0.06, 0.44) 187 0.28 (0.09, 0.47) 1.19 (0.68, 2.08) 
OR         0.98 (0.34, 2.83)         2.03 (0.76, 5.40) 2.07 (0.94, 4.57) 
P-value                                                                                 0.07 
            
High Risk            
Control 76 0.34 (0.17, 0.52) 129 0.34 (0.20, 0.47) 0.96 (0.53, 1.77) 
Intervention 56 0.29 (0.11, 0.47) 108 0.30 (0.17, 0.44) 1.06 (0.52, 2.17) 
OR         0.79 (0.36, 1.76)         0.87 (0.47, 1.59) 1.10 (0.43, 2.80) 
P-value                                                                                 0.85 
            
Any Narcotic Rx            
Low Risk            
Control 134 0.28 (0.16, 0.41) 258 0.23 (0.16, 0.31) 0.76 (0.46, 1.27) 
Intervention 118 0.34 (0.19, 0.48) 187 0.24 (0.15, 0.33) 0.62 (0.36, 1.08) 
OR                                  1.29 (0.71, 2.33)                                  1.06 (0.65, 1.73) 0.82 (0.39, 1.73) 
P-value                                                                                                                                                                                                                     0.61
            
Medium Risk            
Control 120 0.56 (0.34, 0.78) 227 0.47 (0.34, 0.61) 0.70 (0.43, 1.13) 
Intervention 99 0.48 (0.27, 0.68) 187 0.48 (0.33, 0.63) 1.00 (0.59, 1.70) 
OR         0.71 (0.40, 1.27)         1.02 (0.67, 1.56) 1.43 (0.70, 2.92) 
P-value                                                                                 0.33 
            
High Risk            
Control 76 0.72 (0.33, 1.11) 129 0.67 (0.39, 0.95) 0.81 (0.42, 1.55) 
Intervention 56 0.66 (0.26, 1.05) 108 0.61 (0.33, 0.88) 0.81 (0.40, 1.64) 
OR         0.74 (0.33, 1.68)         0.74 (0.40, 1.39) 1.00 (0.38, 2.61) 
P-value                                                                                 1.00 
            
            
 
 
